Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

HUYA Bioscience and Quintiles to Develop New Cancer Therapy

By Pharmaceutical Processing | September 29, 2010

HUYA Bioscience International, a leader in
U.S.-China pharmaceutical co-development, and Quintiles, a fully integrated
biopharmaceutical services company offering clinical, commercial, consulting
and capital solutions worldwide, have announced an agreement to co-develop a
new cancer drug, HBI-8000, sourced in China by HUYA.

HUYA was one of the first companies to recognize the
potential of China
as a source for novel pre-clinical and clinical stage compounds and pioneered
an innovative co-development model. HUYA partners with Chinese research
institutions and pharmaceutical companies to leverage and extend their research
efforts, accelerate development, and provide a bridge to the U.S. development process and
worldwide pharmaceutical markets. HUYA licensed all ex-China rights to HBI-8000
from Chipscreen Bioscience.

HBI-8000 has now entered a Phase I clinical trial in the U.S. under an IND application with the FDA. This trial is
designed to assess safety, tolerability and antitumor activity of HBI-8000 in
patients with advanced solid tumors and lymphomas. Currently, HUYA is planning U.S.

Phase II clinical trials and discussing partnerships with pharmaceutical
companies interested in advancing the development and commercialization of
HBI-8000. The drug has completed Phase I trials in China, in which it exhibited
encouraging antitumor efficacy and a favorable toxicity profile. Chipscreen
Bioscience is now conducting Phase II studies in China.

“This alliance with Quintiles further validates HUYA’s
business model of co-developing novel compounds originating in China
as therapies for global markets,” said Mireille Gingras, Ph.D., CEO of
HUYA. “The initiation of the Phase I trial for HBI-8000 in the U.S.
is a significant achievement for HUYA. It represents both an important development
milestone for this promising cancer drug and illustrates the benefits of
Chinese and Western biopharmaceutical companies working together to efficiently
carry out drug development. This important step will expedite the clinical
development process of HBI-8000 in the U.S.
and Europe. Our hope is that this drug will benefit
cancer patients globally.” “This agreement will help accelerate the
development of medicines from China,”
said Tom Perkins, Senior Vice President of the Capital group at Quintiles.
“It illustrates Quintiles’ ability to draw upon its breadth of services to
build alliances that help biopharmaceutical companies navigate the New Health,
and further illustrates our strategy to maximize the potential of global
biopharmaceutical development and innovation for the benefit of patients.”
  

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE